Singapore, May 8, 2008: Eisai Corporation of North America has appointed Ms Cynthia Schwalm as President of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the US commercial operation of Eisai Co., of Japan.

Ms Schwalm brings to Eisai Inc. a strong track record of building high-performing organizations that drive global growth and nearly 25 years of senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices. She will report to Mr Lonnel Coats, President & COO, Eisai Corporation of North America. Previously, Mr. Coats held dual responsibilities, also serving as President & COO of Eisai Inc.

Ms Schwalm joins Eisai from Amgen, where over the course of her five-year tenure she rose to Vice President and General Manager of the US Oncology Business Unit, a group with annual revenues exceeding $5 billion. In this role she led the 500-person business unit, oversaw all oncology strategy and served as a member of Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory, and health economic functions.

Prior to Amgen, Ms Schwalm grew her pharmaceutical career over an 18-year period within Johnson & Johnson (J&J), holding positions of increasing responsibility at various J&J companies. During this time, she gained experience in oncology commercialization and also developed sales and marketing expertise in critical care, neurology/analgesia and gastroenterology. In her last assignment at J&J, she spent several years in the United Kingdom as the Managing Director of Ortho Biotech UK & Ireland.

Ms Schwalm holds a Bachelor of Science degree in nursing from the University of Delaware and a Master of Business Administration degree from the Wharton School, University of Pennsylvania.